Discussions also delved into the complexities of value-based oncology care, the growing role of real-world data, and strategies to improve access to care in hematology. Across all sessions, a common ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly already has market share in the breast cancer space with the approved drug Verzenio (abemaciclib), and is advancing investigational drugs like the oral selective estrogen receptor degrader ...

CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising ...

The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.

Scorpion has been collaborating with Pfizer to study STX-678 together with a so-called CDK4 inhibitor. Lilly sells a drug, called Verzenio, that similarly targets CDK4 alongside a related protein.

Currently, there are three CDK4/6 inhibitors approved to treat breast cancer at different stages — Ibrance (chemical name: palbociclib), Kisqali (chemical name: ribociclib), and Verzenio (chemical ...

Abemaciclib (Verzenio / Verzenios / Yulareb / Zenlistik) is a benzimidazole derivative, acts as an anti-tumor or anti-neoplastic agent. It is formulated as tablets and film coated tablets for the oral ...

There are several different CD4/CD6 inhibitors on the market, including Ibrance, Kisqali, and Verzenio. A class of medications called CD4/CD6 inhibitors are being used more and more for women battling ...

Verzenio’s label expanded to include the full study population investigated in the Verzenio Phase 3 monarchE trial. Approval supported by four-year data from the monarchE trial; Verzenio added to ...